Michael Ryskin
Stock Analyst at B of A Securities
(1.43)
# 3,306
Out of 4,873 analysts
35
Total ratings
47.83%
Success rate
-2.31%
Average return
Main Sectors:
Stocks Rated by Michael Ryskin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TEM Tempus AI | Maintains: Neutral | $48 → $68 | $68.28 | -0.41% | 5 | May 20, 2025 | |
| MRVI Maravai LifeSciences Holdings | Maintains: Buy | $9 → $8 | $2.23 | +258.74% | 3 | Mar 3, 2025 | |
| IDXX IDEXX Laboratories | Maintains: Neutral | $475 → $535 | $530.50 | +0.85% | 2 | Feb 4, 2025 | |
| ALGN Align Technology | Maintains: Underperform | $200 → $206 | $186.58 | +10.41% | 6 | Dec 13, 2024 | |
| GH Guardant Health | Maintains: Buy | $28 → $40 | $49.99 | -19.98% | 1 | Jul 18, 2024 | |
| ALIT Alight | Maintains: Buy | $10 → $9.5 | $5.50 | +72.73% | 1 | Jun 25, 2024 | |
| CERT Certara | Maintains: Buy | $27 → $24 | $10.69 | +124.51% | 2 | Aug 15, 2023 | |
| AVTR Avantor | Maintains: Buy | $27 → $24 | $13.46 | +78.31% | 2 | Jul 31, 2023 | |
| ZTS Zoetis | Maintains: Buy | $225 → $180 | $157.77 | +14.09% | 7 | Nov 4, 2022 | |
| RXRX Recursion Pharmaceuticals | Downgrades: Neutral | n/a | $5.22 | - | 2 | Apr 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $80 → $52 | $20.60 | +152.43% | 2 | Nov 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $17 → $10 | $2.81 | +255.87% | 2 | Nov 10, 2021 |
Tempus AI
May 20, 2025
Maintains: Neutral
Price Target: $48 → $68
Current: $68.28
Upside: -0.41%
Maravai LifeSciences Holdings
Mar 3, 2025
Maintains: Buy
Price Target: $9 → $8
Current: $2.23
Upside: +258.74%
IDEXX Laboratories
Feb 4, 2025
Maintains: Neutral
Price Target: $475 → $535
Current: $530.50
Upside: +0.85%
Align Technology
Dec 13, 2024
Maintains: Underperform
Price Target: $200 → $206
Current: $186.58
Upside: +10.41%
Guardant Health
Jul 18, 2024
Maintains: Buy
Price Target: $28 → $40
Current: $49.99
Upside: -19.98%
Alight
Jun 25, 2024
Maintains: Buy
Price Target: $10 → $9.5
Current: $5.50
Upside: +72.73%
Certara
Aug 15, 2023
Maintains: Buy
Price Target: $27 → $24
Current: $10.69
Upside: +124.51%
Avantor
Jul 31, 2023
Maintains: Buy
Price Target: $27 → $24
Current: $13.46
Upside: +78.31%
Zoetis
Nov 4, 2022
Maintains: Buy
Price Target: $225 → $180
Current: $157.77
Upside: +14.09%
Recursion Pharmaceuticals
Apr 18, 2022
Downgrades: Neutral
Price Target: n/a
Current: $5.22
Upside: -
Nov 11, 2021
Downgrades: Neutral
Price Target: $80 → $52
Current: $20.60
Upside: +152.43%
Nov 10, 2021
Downgrades: Underperform
Price Target: $17 → $10
Current: $2.81
Upside: +255.87%